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Benzodiazepines remain widely used for the treatment of anxiety
disorders despite prominent, often limiting side effects including
sedation, muscle relaxation, and ataxia. A compound producing a
robust anxiolytic action comparable to benzodiazepines, but lack-
ing these limiting side effects at therapeutic doses (an anxioselec-
tive agent), would represent an important advance in the treat-
ment of generalized anxiety disorder, and perhaps other anxiety
disorders. Here we report that the pyrazolo[1,5-a]-pyrimidine,
ocinaplon, exhibits an anxioselective profile in both preclinical
procedures and in patients with generalized anxiety disorder, the
most common of the anxiety disorders. In rats, ocinaplon produces
significant muscle relaxation, ataxia, and sedation only at doses
>25-fold higher than the minimum effective dose (3.1 mgkg) in
the Vogel ‘‘conflict’’ test. This anticonflict effect is blocked by
flumazenil (Ro 15–1788), indicating that like benzodiazepines,
ocinaplon produces an anxiolytic action through allosteric modu-
lation of GABAA receptors. Nonetheless, in eight recombinant
GABAA receptor isoforms expressed in Xenopus oocytes, the po-
tency and efficacy of ocinaplon to potentiate GABA responses
varied with subunit composition not only in an absolute sense, but
also relative to the prototypical benzodiazepine, diazepam. In a
double blind, placebo controlled clinical trial, a 2-week regimen of
ocinaplon (total daily dose of 180–240 mg) produced statistically
significant reductions in the Hamilton rating scale for anxiety
scores. In this study, the incidence of benzodiazepine-like side
effects (e.g., sedation, dizziness) in ocinaplon-treated patients did
not differ from placebo. These findings indicate that ocinaplon
represents a unique approach both for the treatment and under-
standing of anxiety disorders.
generalized anxiety disorder  benzodiazepines
Benzodiazepines remain widely used for the treatment of anxietydisorders (1, 2) despite significant limiting side effects including
sedation, muscle relaxation, and ataxia. This spectrum of pharma-
cological actions is produced by augmenting the actions of the
inhibitory neurotransmitter GABA through an allosteric modula-
tion of GABAA receptors (3, 4), a family of heteropentameric,
ligand-gated ion channels (5). Although there are at least seven
subunit classes, the majority of GABAA receptors are composed of
-, -, and -subunits (6), with multiple subtypes of each that can
assemble to form GABA-gated ion channels (5, 7). This subunit
repertoire allows for remarkable receptor diversity, and 12 dis-
tinct GABAA receptor isoforms may be present in the mammalian
nervous system (8).
Benzodiazepines bind to and act upon a subset of GABAA
receptors containing - and -subunits in combination with 1-,
2-, 3-, or 5-subunits. The identification of novel molecules
acting at the benzodiazepine recognition site of the GABAA
receptor began 25 years ago (9, 10), and remains an area of
intense interest (2, 5, 11, 12). The impetus for identifying such
molecules was the discovery that the triazolopyridazine, CL 218,872
(9, 10), exhibited selectivity for ‘‘Type I’’ benzodiazepine receptors
(subsequently identified as GABAA receptors containing an 1-
subunit; refs. 5 and 13) and a low efficacy relative to benzodiaz-
epines in potentiating GABA-gated chloride currents (14, 15). CL
218,872 produced anxiolytic-like effects in animal models at doses
substantially lower than those producing benzodiazepine-like side
effects (e.g., sedation, ataxia, muscle relaxation) (16). A compound
exhibiting this ‘‘anxioselective’’ profile in humans would represent
a significant advance in the treatment and understanding of anxiety
disorders.
A number of compounds have been identified that exhibit
GABAA receptor subtype selectivity andor lower efficacy than
benzodiazepines to enhance GABA-stimulated chloride currents
(reviewed in ref. 2). Some compounds, such as bretazenil and
abecarnil, exhibit an anxioselective profile in animals (17, 18), but
data from clinical trials do not support the anxioselectivity pre-
dicted from preclinical results (19, 20). We now report that oci-
naplon (DOV 273,547; 2-pyridinyl[7-(4-pyridinyl)pyrazolo[1,5-a]-
pyrimidin-3-yl]methanone) fulfills both preclinical and clinical
criteria for an anxioselective agent.
Methods
‘‘Thirsty Rat’’ Conflict Test. The procedure used in this study was
essentially as originally described by Vogel et al. (21). The effects of
drugs or vehicle (n  8 animals per dose) were evaluated 1 h after
oral administration. See Supporting Text, which is published as
supporting information on the PNAS web site, for further details.
Blockade of Pentylenetetrazole-Induced Convulsions. The anticon-
vulsant properties of ocinaplon and diazepam were evaluated
essentially as described (10, 22) using pentylenetetrazole (19 mgkg,
i.v.) as the convulsant agent. Rats (n  4 per dose) were challenged
with pentylenetetrazole 1 h after oral administration of ocinaplon,
diazepam, or vehicle. See Supporting Text for further details.
Evaluation of Motor Function in Rats. Motor activity. One hour after
oral administration of ocinaplon, diazepam, or vehicle, individual
animals (n  12–24 per dose) were placed in activity chambers
equipped with photoelectric cells, and activity was recorded for 5
min. The ED50 was the dose that reduced activity levels to 50% in
comparison with vehicle-treated control animals (10).
Inclined screen. Rats (n  8 per dose) were placed individually on an
inclined screen (60°) 1 h after oral administration of vehicle,
ocinaplon, or diazepam. The number of animals remaining on the
screen for at least 30 min was recorded. The ED50 is the dose
producing screen failures in 50% of the rats (10).
Rod walking. Rats were trained to traverse a wooden rod inclined at
17°. One hour after orally administered diazepam and ocinaplon,
the number of animals (n  10 per dose) unable to traverse the rod
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was evaluated (22). The ED50 was that dose causing 50% of the rats
to fall. ED50 values were calculated by the probit analysis method
of Finney (23).
Squirrel Monkey Conflict Procedure. The effects of ocinaplon, diaz-
epam, and vehicle were evaluated in a conflict procedure (22, 24)
using adult, male squirrel monkeys (Saimiri sciureus). Drugs or
vehicle were administered by gavage 60 min before placing the
animals in the operant conditioning chamber. The mean reinforced
responses, mean conflict responses, and mean conflict response
failures were calculated for each dosage level. Significant differ-
ences between drug responding and control level (obtained on the
day before treatment) were determined by using a paired t test. See
Supporting Text for further details.
Clinical Study in Generalized Anxiety Disorder. Twenty centers in
Germany received Ethics Committee approval to participate in this
study, with 15 centers enrolling patients. The study was performed
in accordance with the declaration of Helsinki, Good Clinical
Practice on Medicinal Products in the European Community, Food
and Drug Administration Good Clinical Practice Regulations, and
International Harmonization Good Clinical Practice Guidelines.
Study-related procedures were not initiated until a subject had
given written informed consent on an Institutional Review Board-
approved consent form. Eligible outpatients 18 years of age who
met the DSM-IV criteria for general anxiety disorder (GAD), had
sufficient initial symptom severity to require treatment [total score
on the Hamilton Rating Scale for Anxiety (HAM-A)  22], and did
not have coexisting depressive symptoms [total score on the Ham-
ilton Rating Scale for Depression (HAM-D)  15] were included
in a placebo run-in period (single-blind, 1-week dosing). Those
individuals whose HAM-A scores did not decrease by 10%
during the run-in period were enrolled in a 14-day, double-blind
treatment period and randomized to one of three treatment groups.
In addition to the principal efficacy measure, change in the
HAM-A (25), secondary measures of efficacy included the clinical
global impression scale, and the patient’s self-rating scale for
generalized anxiety (26). Repeated weekly assessments of symptom
severity over time served as the dependent variable in the analyses
for efficacy. Adverse experiences were evaluated at baseline (i.e.,
end of screeningplacebo run-in period) and at the beginning of
every week thereafter. Each nonlaboratory adverse experience
reported by the patients was rated for its severity and for its
relationship with the study drug. Vital signs were evaluated by
monitoring sitting blood pressure, respiratory rate, temperature,
and pulse rate. Screening and safety analysis consisted of blood
chemistry and liver function tests in conjunction with urinalysis and
hematologic testing (complete blood count).
Inhibition of Radioligand Binding to Native GABAA Receptors. The
ability of ocinaplon to inhibit [3H]flunitrazepam binding to native
GABAA receptors prepared from rat cortical and cerebellar mem-
Fig. 1. Anticonflict actions of ocinaplon and diazepam: blockade by fluma-
zenil. Adult, male CD rats (Charles River Breeding Laboratories) were orally
administered vehicle (0.5% methylcellulose containing 0.1% Tween 80), oci-
naplon, or diazepam suspended in vehicle. Sixty minutes later, the effect of
these treatments was evaluated in the ‘‘thirsty rat conflict’’ test, essentially as
described (21). Flumazenil (12.5 mgkg, i.p.) was administered 30 min before
testing. This dose of flumazenil does not affect performance in the thirsty rat
conflict test (data not shown). The minimum effective dose (the first dose
producing a statistically significant difference from vehicle treated rats) of
both ocinaplon and diazepam was 3.1 mgkg. Values represent the mean (n 
8 animals per dose) increase in punished responding compared to vehicle
treated rats. Open circles, ocinaplon; open squares, diazepam; filled circles,
ocinaplon plus flumazenil; filled squares, diazepam plus flumazenil.
Fig. 2. Effects of ocinaplon and diazepam on motor function in rats.
Compounds were evaluated 60 min after oral administration. (Top) Motor
activity. Values represent the mean % decrease in motor activity of 12–24 rats
per dose compared to vehicle treated animals. The ED50 of diazepam and
ocinaplon was 17.5 and 81.7 mgkg, respectively. (Middle) Inclined screen. The
effect of diazepam and ocinaplon was evaluated on the ability of rats to
remain on an inclined (60°) screen for 30 min. The ED50 of diazepam and
ocinaplon was 15.5 (3.5–24.9, 95% CI) and 172.2 (123.3–244.5, 95% CI) mgkg,
respectively. (Bottom) Rod walking. Animals were trained to traverse a rod
inclined at 17°. Values represent the mean of 10 rats per dose. The ED50 of
diazepam and ocinaplon was 13.8 (2.7–20.4, 95% CI) and 92 (68–124, 95% CI)
mgkg, respectively.









branes was performed essentially as described (ref. 27; see Sup-
porting Text for further details).
Evaluation of GABA-Gated Currents in Recombinant Human GABAA
Receptors Expressed in Xenopus Oocytes. cRNAs encoding GABAA
receptor 1, 2-, 3-, or 5-, 2, and 2- or 3-subunits were microin-
jected into Xenopus laevis oocytes. Forty-eight hours later, the
effects of ocinaplon and diazepam were measured on GABA-gated
inward currents using a Warner two-electrode voltage clamp am-
plifier in voltage clamp mode as described (see ref. 28 and Sup-
porting Text for further details).
Animals. Studies in both rats and monkeys were conducted at
Lederle Laboratories (Pearl River, NY). Protocols were approved
by the Animal Care and Use Committee consistent with National
Institutes of Health guidelines. Studies in X. laevis frogs were
approved by the Animal Care and Use Committee, Boston Uni-
versity School of Medicine. Male CD rats (Charles River Breeding
Laboratories) weighing 120–220 g were used in these experiments.
Adult, male squirrel monkeys (S. sciureus) were obtained from a
local colony. Female, oocyte-positive X. laevis frogs were purchased
from Xenopus One (Ann Arbor, MI) or Nasco (Fort Atkinson, WI).
Drugs. Ocinaplon was manufactured by ACRAF SpA (Aprilia,
Italy). Diazepam, flumazenil, and other reagents were obtained
from SigmaResearch Biochemicals. Drugs were suspended in
0.5% methylcellulose containing 0.1% Tween 80.
Results
Preclinical Studies in Rodents and Primates. The ability of a drug to
increase punished responding in ‘‘conflict’’ procedures is highly
predictive of an antianxiety effect in humans (21, 22, 29). Ocinaplon
produced a dose-related increase in punished responding in a
‘‘thirsty rat’’ conflict procedure (21) with a potency and efficacy
comparable to the prototypic benzodiazepine, diazepam (Fig. 1).
The minimum effective dose for each drug was 3.1 mgkg when
administered orally 1 h before testing. The ability of flumazenil (Ro
15–1788) to antagonize the anticonflict action of ocinaplon (Fig. 1)
indicates that, like benzodiazepines (30), this effect is mediated by
GABAA receptors. Furthermore, ocinaplon was as potent and
effective as diazepam in reducing pentylenetetrazole-induced con-
vulsions [ED50 values of 9.6 (95% CI; range, 7.9–12.1) mgkg and
7.5 (95% CI; range, 5.3–10.6) mgkg orally, respectively], another
preclinical test that is highly predictive of an antianxiety effect in
humans (22).
Ocinaplon produced performance deficits comparable to diaz-
epam in the motor activity, rod-walking, and inclined screen tests
(Fig. 2) that are considered predictive of side effects (sedation,
ataxia, and muscle relaxation, respectively) typically associated with
benzodiazepines (22). However, ocinaplon was 5- to 10-fold less
potent than diazepam in disrupting performance in these tests, in
contrast to its potency in the thirsty rat conflict and antipentyle-
netetrazole tests. This differential potency of ocinaplon in rodents
is consistent with the profile of an ‘‘anxioselective’’ agent.
Ocinaplon produced a similar anxioselective profile in nonhu-
man primates. Squirrel monkeys were trained to bar press under
conditions of both reward and punishment in a conflict procedure
that is sensitive to clinically effective anxiolytics (22, 24). The
minimum effective dose (MED) for ocinaplon to increase punished
responding was 4 mgkg orally; a significant increase in punished
responding was maintained until a dose of 64 mgkg. At a dose of
128 mgkg, both punished and food reinforced responding were
decreased (Fig. 3). The MED for diazepam to increase punished
responding in this procedure was 0.5 mgkg. However, this anti-
conflict effect was no longer apparent at doses 2 mgkg, pre-
Fig. 3. Anticonflict actions of ocinaplon (Upper) and diazepam (Lower) in
primates. Punished and nonpunished responding in adult, male squirrel mon-
keys was performed as described (24). Drugs were administered orally 60 min
before a test session. A profound sedation was noted in animals administered
4 mgkg diazepam. Although a significant reduction in nonpunished respond-
ing was observed with ocinaplon at 128 mgkg, overt signs of sedation were
not noted. Filled bars, punished (conflict) responding; open bars, unpunished
responding; *, P  0.05 paired t test.
Fig. 4. Anxiolytic effects of ocinaplon in GAD. Eligible patients with a
diagnosis (HAM-A score of 20 at the end of the 1-week placebo run-in
period) of GAD were randomized into three groups receiving placebo, 180 mg
of ocinaplon (60 mg three times daily), or 240 mg of ocinaplon (120 mg twice
daily) for 14 days. For each group and each time point, the depicted values
represent the mean total score on the HAM-A scale of evaluable patients
completing the study with no protocol deviation. The overall effect of oci-
naplon on HAM-A scores was significantly different (P  0.007) compared with
placebo. Filled circles, placebo; open circles, ocinaplon, 180 mgday; filled
squares, ocinaplon 240 mgday; a: t  1.7, df  66, P  0.09 for Ocinaplon, 180
mgday vs. placebo; b, t  3.1, df  62, P  0.003 for Ocinaplon 240 mgday
vs. placebo. These t values represent the dose  time interaction for each
individual dose of ocinaplon.
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sumably because of disruption of motor activity that also signifi-
cantly reduced responding under a reinforcing (nonpunishment)
schedule at a dose of 4 mgkg (Fig. 3).
Ocinaplon in Patients with GAD. Based on these preclinical results,
we initiated a multicenter, double-blind, placebo-controlled safety
and efficacy study of ocinaplon in GAD. Eligible patients were
enrolled in a 14-day double-blind treatment period and randomized
to one of three treatment groups: placebo (n  42), 60 mg of
ocinaplon three times a day (TID) (n  43), or 120 mg of ocinaplon
twice daily (BID) (n  42). The principal efficacy measure was
change in the HAM-A score at the end of the 2-week study.
Hierarchical linear modeling analysis of HAM-A scores obtained
from the intent-to-treat (ITT) population comprising all random-
ized subjects (including patients who did not complete the trial)
yielded a significant interaction between time and treatment (t 
2.6, P  0.011) for the global contrast between ocinaplon and
placebo. Patients assigned to placebo displayed a mean reduction in
HAM-A scores of 9.7  1.4 (standard error) points (P  0.001)
after 2 weeks, whereas the reduction in total HAM-A scores in
patients assigned to the 60-mg ocinaplon TID and 120-mg oci-
naplon BID arms were 14.1  1.9 and 15.3  1.9 points, respec-
tively. Analyses of the individual treatment group contrasts in the
ITT population for the 2-week data demonstrated that 120-mg
ocinaplon BID elicited a significantly greater reduction in symptom
severity compared to placebo (t  2.34, P  0.02). The difference
between 60-mg ocinaplon TID and placebo approached statistical
significance (t  1.89, P  0.06). Investigation of the effect size
estimates indicated that the two doses were essentially identical in
efficacy (with slight numerical advantage for 120-mg ocinaplon BID
compared to 60-mg ocinaplon TID). An analysis of the set of
patients completing the study with no protocol deviation (n  32,
35, and 31 for placebo, 180 mg of ocinaplon, and 240 mg of
ocinaplon, respectively) yielded results (Fig. 4) essentially identical
to those found in the ITT sample. A statistically significant differ-
ence in HAM-A scores for the global contrast between ocinaplon
and placebo was observed as early as 1 week (P  0.022) after the
start of dosing. Statistically significant dose  time interactions
were also observed for each individual dose of ocinaplon (t  1.7,
df  66, P  0.09 for 180 mgday ocinaplon vs. placebo; t  3.1, df 
62, P  0.003 for 240 mgday ocinaplon) compared to placebo. The
reductions in HAM-A scores produced by ocinaplon were paral-
leled by changes in both the clinical global impression and self-
rating scale measures (data not shown).
There were no treatment-emergent, serious adverse events in this
trial. The number of patients in each group with at least one
treatment emergent adverse event in the trial was relatively low
(Table 1), and the proportion of patients with treatment emergent
adverse events was comparable among treatment groups (placebo,
9.5%; 240 mg of ocinaplon, 9.5%; 180 mg of ocinaplon, 11.6%; P 
1.0, Fisher’s exact test). No clinically significant, treatment-
emergent laboratory abnormalities were detected in the study
population. In general, the overall side-effect profile was unremark-
able across the entire study population. Of particular note was an
absence of significant findings or trends for the central nervous
system and other effects normally associated with benzodiazepines
such as sedation and dizziness (Table 1 and refs. 31 and 32).
In Vitro Studies: Native and Recombinant GABAA Receptors. Oci-
naplon selectively inhibited [3H]flunitrazepam binding in a broad
receptor-binding screen using 30 different ligands (data not shown),
consistent with the observation that Ro 15–1788 antagonizes the
anticonflict actions of ocinaplon (Fig. 1). Ocinaplon was 3-fold
more potent in inhibiting [3H]flunitrazepam binding to rat cere-
Table 1. Summary of treatment emergent adverse events (AEs)
MedDRA system organ classification (SOC) MedDRA preferred term







One or more AEs* All patients with AEs 4 (9.5) 5 (11.6) 4 (9.5)
Gastrointestinal disorders Patients with AEs 1 (2.4) 1 (2.3) 1 (2.4)
Abdominal pain upper 1 (2.4) 0 0
Nausea 0 1 (2.3) 1 (2.4)
General disorders and administration site conditions Patients with AEs 1 (2.4) 1 (2.3) 1 (2.4)
Fatigue 1 (2.4) 0 1 (2.4)
Mucous membrane disorder NOS 0 1 (2.3) 0
Immune system disorders Patients with AEs 0 0 1 (2.4)
Conjunctivitis allergic 0 0 1 (2.4)
Investigations Patients with AEs 0 1 (2.3) 0
Heart rate increased 0 1 (2.3) 0
Musculoskeletal and connective tissue disorders Patients with AEs 2 (4.8) 0 2 (4.8)
Back pain 1 (2.4) 0 0
Musculoskeletal chest pain 0 0 1 (2.4)
Neck pain 0 0 1 (2.4)
Torticollis 1 (2.4) 0 0
Nervous system disorders Patients with AEs 0 2 (4.7) 1 (2.4)
Agitation 0 1 (2.3) 0
Sedation 0 1 (2.3) 0
Somnolence 0 1 (2.3) 0
Vertigo 0 0 1 (2.4)
Renal and urinary disorders Patients with AEs 0 1 (2.3) 0
Cystitis NOS 0 1 (2.3) 0
Respiratory, thoracic, and mediastinal disorders Patients with AEs 0 1 (2.3) 0
Sinusitis NOS 0 1 (2.3) 0
Patients reporting individual AEs may not add up to the number of patients within a SOC because a subject may have reported more
than one AE with in a SOC term. MeDRA, medical dictionary regulatory applications; NOS, not otherwise specified.
*No significant difference among treatments in proportion of patients with AEs.









bellum than cortex (IC50 values of 1.2 M and 3.8 M, respectively,
with Hill coefficients 0.9 and 0.7 in cerebellum and cortex, respec-
tively). These radioligand-binding data indicate that compared to
diazepam, the prototypic benzodiazepine, ocinaplon is a low-
affinity ligand at GABAA receptors that exhibits a modest selec-
tivity for GABAA1 receptors (receptors containing 1-subunits; ref.
5), because this subunit is enriched in cerebellum compared to
cortex (6, 33, 34).
To determine how subunit composition influences the molecular
actions of ocinaplon at GABAA receptors, cRNAs corresponding
to specific combinations of 1, 2-, 3-, or 5-, 2, and 2- or 3-subunits
were subcloned and microinjected into X. laevis oocytes. Forty-eight
hours later, the effects of ocinaplon and diazepam were measured
on GABA-gated inward currents in the voltage clamp mode (28).
Both the potency and efficacy (that is, the maximal effect) of
diazepam to potentiate GABA-stimulated chloride currents varied
with subunit composition (Fig. 5 and Table 2). Likewise, the
potency and efficacy of ocinaplon varied with subunit composition
(see Fig. 5 and Table 2), not only in an absolute sense but also
relative to diazepam. Thus, ocinaplon increased GABA-stimulated
chloride currents with efficacies ranging from 25% to 85%
relative to diazepam, and potencies 5- to 35-fold lower than
diazepam across these eight recombinant receptor isoforms. The
greatest relative potentiation of GABA-stimulated currents was
produced in receptors containing the 1-subunit. In those cells
containing the 122 isoform where ocinaplon displayed the
greatest relative efficacy, diazepam was approximately eight times
more potent than ocinaplon in its ability to potentiate GABA-
stimulated currents (see Table 2), a relative potency comparable to
that seen in the squirrel monkey conflict procedure (Fig. 3). The
substitution of a 3-subunit in this 1-containing complex reduced
the relative efficacy of ocincaplon with only a small increase in
relative potency. Similar substitution of a 3-subunit in the 2-, 3-,
and 5-containing complexes produced larger increases in the
relative potency of ocinaplon while decreasing its relative efficacy
(Table 2). Ocinaplon may thus be viewed as a partial positive
modulator at 2-, 3-, and 5-containing receptors because its
efficacy was substantially lower than diazepam at these receptor
isoforms (Table 2).
Discussion
Ocinaplon is anxiolytic in rodents and primates, including humans,
with a magnitude of effect comparable to benzodiazepines. Thus,
in ‘‘conflict’’ procedures that are predictive of anxiolytic activity
(22), ocinaplon produced a maximum response comparable to the
prototypic benzodiazepine diazepam (Figs. 1 and 3). In GAD
patients, the difference from placebo in the HAM-A score (4.4–5.6
points) in both ocinaplon dose groups (180- and 240-mg total daily
dose) after 2 weeks of treatment (Fig. 4) was comparable to the
difference (5.1 points) recently reported after 4 weeks of treatment
with the benzodiazepine, lorazepam (6-mg total daily dose) (32).
However, in contrast to the side effect profile typically produced by
anxiolytic doses of benzodiazepines (e.g., a high incidence of
patients experiencing somnolence, dizziness, and incoordination)
(32), the incidence of adverse events with ocinaplon was not
different from placebo (Table 1). Additional multicenter studies of
longer duration are in progress to confirm both the efficacy of
ocinaplon in reducing the symptoms of GAD and its apparent
anxioselective profile.
Previously published results using genetically modified ‘‘knock-
in’’ mice have emphasized 2-containing receptor isoforms as
critical for mediating the anxiolytic effects of benzodiazepines, and
1-containing isoforms as important for mediating the sedative
effects (35, 36). Thus, at face value, the present results are at
variance with these previously reported data because ocinaplon was
most potent and efficacious, both in an absolute sense and relative
to diazepam, in receptors containing 1-subunits. Several different
interpretations might explain this apparent inconsistency.
First, it is possible that ocinaplon and benzodiazepines act on
different GABAA receptor subtypes such that ocinaplon produces
its anxiolytic effects through actions on 1-containing complexes,
whereas benzodiazepines and perhaps other structural classes of
compounds (11, 12) produce anxiolytic effects through actions on
2-containing (GABAA2) receptors. This hypothesis is presently
Fig. 5. Potentiation of GABA-gated currents by ocinaplon and diazepam in
recombinant rat GABAA receptors expressed in Xenopus oocytes. Potentiation
was determined by using an EC10 concentration of GABA. Curves were fitted
by using nonlinear regression analysis and represent the mean values ob-
tained from at least five oocytes harvested from at least two batches. Open
circles, diazepam; filled circles, ocinaplon.
7384  www.pnas.orgcgidoi10.1073pnas.0502579102 Lippa et al.
under investigation in selectively bred ‘‘knock-in’’ mice expressing
either GABAA1 or GABAA2 receptors that are insensitive to
benzodiazepines (35–37). Second, it is possible that only partial
activation of 2-containing GABAA receptors by ocinaplon is
sufficient to produce a full anxiolytic effect. The low efficacy of
L-838,417 (which exhibits an anxioselective profile in animals)
relative to benzodiazepines at 2-containing receptors is consistent
with this hypothesis (12, 36). However, this hypothesis does not
adequately explain the anxioselective property of ocinaplon, given
its potency and efficacy at 1-containing receptors, which are
presumed to mediate the sedative effects of benzodiazepines. A
variation of this hypothesis posits that anxiolysis requires that a
compound produce only partial activation, whereas ‘‘side effects’’
require full activation of GABAA receptors relative to a benzodi-
azepine. However, this hypothesis may also be viewed as flawed
because ocinaplon, despite its partial agonist profile at 2-, 3-, and
5-containing receptors (Fig. 5 and Table 2), produces sedation,
muscle relaxation, and ataxia, albeit at doses more than one order
of magnitude higher than those producing an anxiolytic effect.
Rather, a combination of high relative potency and high relative
efficacy at certain receptor subtypes would seem to more parsimo-
niously explain its anxioselective properties. Finally, although stud-
ies using knock-in mice indicate that GABAA1 receptors contribute
to the sedative and anticonvulsant properties of benzodiazepines
(36, 37), pharmacological studies using a selective GABAA1 antag-
onist (38, 39) indicate that the anticonflict (but not the motor
impairing) actions of diazepam (11, 40) are mediated via GABAA1
receptors. There are other significant inconsistencies between data
obtained in knock-in mice and pharmacological studies using
subtype selective pharmacological agents in wild type animals (41).
It is not known whether such differences relate to the behavioral
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tive action in the clinic. The present results demonstrate ocinaplon
represents both a significant advance in the treatment of general-
ized anxiety disorder and a unique tool for studying the molecular
substrates of anxiety.
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Table 2. Potencies and efficacies of diazepam and ocinaplon in recombinant GABAA receptors
Receptor
composition








M pEC50 EC50 Emax
122S 103  8.4 0.36 6.45  0.06 88  8.6 3.07 5.51  0.14 8.6 0.85
123 90  8.0 1.95 5.71  0.06 51  3.5 10.03 5.00  0.05 5.1 0.57
222S 108  13.5 0.16 6.81  0.06 52  8.8 3.39 5.47  0.07 21.9 0.48
223 127  4.2 0.78 6.11  0.02 46  5.2 3.83 5.42  0.04 4.9 0.36
322S 159  16.9 0.20 6.71  0.14 78  7.1 4.59 5.34  0.06 23.5 0.49
323 166  14.8 1.58 5.80  0.04 41  4.5 9.02 5.05  0.05 5.7 0.25
522S 154  8.0 0.11 6.96  0.07 61  4.2 3.79 5.42  0.07 34.8 0.40
523 74  9.9 1.36 5.87  0.03 22  0.2 7.40 5.13  0.05 5.4 0.30
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